Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse

Eur J Heart Fail. 2010 Apr;12(4):319-22. doi: 10.1093/eurjhf/hfq017.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Animals
  • Antibodies / immunology*
  • Antirheumatic Agents / pharmacology
  • Antirheumatic Agents / therapeutic use
  • Cytokines
  • Disease Models, Animal
  • Disease Progression
  • Genetic Engineering
  • Heart Failure / etiology*
  • Heart Failure / physiopathology
  • Heart Failure / prevention & control
  • Interleukin 1 Receptor Antagonist Protein / pharmacology*
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use
  • Interleukin-1beta*
  • Male
  • Mice
  • Mice, Inbred ICR
  • Myocardial Infarction / complications*
  • Myocardial Infarction / diagnostic imaging
  • Receptors, Interleukin-2 / drug effects
  • Ultrasonography
  • Ventricular Remodeling*

Substances

  • Antibodies
  • Antirheumatic Agents
  • Cytokines
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1beta
  • Receptors, Interleukin-2